Combined immune checkpoint inhibitors of CTLA4 and PD-1 for hepatic melanoma of unknown primary origin: A case report
Open Access
- 16 April 2021
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 9 (11), 2641-2648
- https://doi.org/10.12998/wjcc.v9.i11.2641
Abstract
Melanoma is uncommonly found in lymph nodes, subcutaneous tissue, or visceral organs without a primary lesion, where it is identified as metastatic melanoma with unknown primary (MUP). Hepatic MUP is extremely rare and has a poor prognosis. There is limited information on its pathogenesis, clinical and imaging features, and pathological findings. There are no guidelines for the use of immune checkpoint inhibitors (ICIs) in hepatic MUP, and the treatment outcome has rarely been reported. A 42-year-old woman presented to our hospital with hepatic tumors found incidentally during a routine check-up. Contrast-enhanced abdominal com-puterized tomography showed multiple mass lesions in the liver. Pathological results revealed melanoma, which was confirmed by immunohistochemical staining for HMB-45(+), Melan-A(+), S-100(+), and SOX10(+). There was no evidence of primary cutaneous, ocular, gastrointestinal, or anal lesion on a comprehensive examination. The patient was diagnosed with hepatic MUP. She received combined antibodies against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4, ipilimumab) and programmed death protein-1 (PD-1, nivolumab). She died of hepatic failure 9 mo after hepatic MUP was diagnosed. This the first case of hepatic MUP treated with combined ipilimumab and nivolumab, who showed better outcome than previous cases. Combined ICIs of PD-1 and CTLA-4 may be considered as the first-line therapy for patients with hepatic MUP.Keywords
This publication has 24 references indexed in Scilit:
- Metastatic melanomas of unknown primary show better prognosis than those of known primary: A systematic review and meta-analysis of observational studiesJournal of the American Academy of Dermatology, 2015
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated MelanomaThe New England Journal of Medicine, 2014
- Liver Metastases of Unknown Primary: Malignant MelanomaCase Reports in Hepatology, 2014
- Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009Melanoma Research, 2011
- Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literatureCritical Reviews in Oncology/Hematology, 2011
- Improved Survival for Stage IV Melanoma From an Unknown Primary SiteJournal of Clinical Oncology, 2009
- Improved Survival After Lymphadenectomy for Nodal Metastasis From an Unknown Primary MelanomaJournal of Clinical Oncology, 2008
- Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patientsCancer Immunology, Immunotherapy, 2005
- Fulminant hepatic failure caused by malignant melanoma of unknown primary originThe Esophagus, 2004
- Primary melanoma tumour regression associated with an immune response to the tumour‐associated antigen melan‐A/MART‐1International Journal of Cancer, 2001